NAD+
Medium EvidenceA coenzyme essential for cellular energy production, studied for anti-aging and metabolic support.
What It Is
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell, essential for cellular energy metabolism, DNA repair, sirtuin activation, and over 500 enzymatic reactions. While not a peptide, NAD+ is widely discussed alongside peptide protocols due to its role in metabolic optimization and its intersection with peptide targets like MOTS-c and 5-Amino-1MQ (which boosts NAD+ via NNMT inhibition). Intracellular NAD+ levels decline significantly with age — approximately 50% by middle age — and this decline is implicated in mitochondrial dysfunction, impaired DNA repair, reduced sirtuin activity, and age-related metabolic disease. NAD+ precursors (NMN, NR) and direct IV NAD+ infusion are the primary supplementation strategies. A 2024 meta-analysis of 15 randomized controlled trials found that NMN supplementation (250–1200 mg/day) consistently increased blood NAD+ metabolites, with some trials showing improvements in physical performance, insulin sensitivity, and vascular function in older adults. IV NAD+ infusions bypass first-pass metabolism and produce rapid increases in whole-blood NAD+ levels, though clinical evidence for IV routes remains limited to small, non-randomized studies. The CD38 enzyme, which degrades NAD+ and increases with aging and chronic inflammation, has emerged as a key pharmacological target. NAD+ supplementation is not FDA-approved for any medical condition but is commercially available as a dietary supplement (precursors) and through wellness clinics (IV infusions). Long-term safety data beyond 12 months remains limited. In June 2026, Noom announced that NAD+ therapies will be part of the expanded healthy-aging formulary enabled by its acquisition of 503A compounding pharmacy Tailor Made Compounding, reflecting accelerating mainstream telehealth distribution of longevity-focused compounds.
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Human (RCT, 2026) | 65 healthy adults — NMN and NR at 1,000 mg/day for 14 days | Doubled circulating NAD+ levels; NMN and NR performed comparably | Source |
| Human (2026) | 11 healthy men — 1,200 mg/day NMN for 7 days after intense exercise | Reduced inflammatory signals post-exercise | Source |
| Human (RCT) | Rare diseases with premature aging and DNA damage | Promising therapeutic benefits from NAD+ supplementation | Source |
| Human (RCT) | Chronic NMN supplementation in healthy older men | Elevated blood NAD+ levels; altered muscle function | Source |
Commonly Discussed Benefits
Researching NAD+? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- IV administration should be performed by medical professionals
- Oral precursors (NMN, NR) are available as supplements but NMN's supplement status is legally contested
- FDA ruled in 2022 that NMN cannot be marketed as a dietary supplement
- Optimal dosing and delivery method still being studied
- A 2025 lifespan study showed no difference vs placebo — anti-aging claims remain under investigation
- Clinical results across studies are mixed; not all trials show meaningful benefits
Comparisons
See how NAD+ compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Rajman L. et al. — Therapeutic potential of NAD-boosting molecules. Cell Metab. 2018 PubMed
- [2] Promising Results With NAD Supplementation in Rare Diseases With Premature Aging and DNA Damage — PMC 2026 PubMed
- [3] Updated Review on NMN and NR Mechanisms, Pre-Clinical and Clinical Comparisons — Food Frontiers. 2025 PubMed
- [4] Longevity.Technology — Noom buys pharmacy to push into healthy aging PubMed
Keep researching in the app
- Log NAD+ to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
Epithalon
Low EvidenceA tetrapeptide studied for its potential to activate telomerase and influence biological aging markers.
MOTS-c
Low EvidenceA mitochondrial-derived peptide studied for metabolic regulation, exercise mimetic effects, and longevity.
SS-31
High EvidenceA mitochondria-targeted peptide FDA-approved as FORZINITY (elamipretide) for Barth syndrome in September 2025 — the first FDA-approved mitochondrial-targeted therapeutic.